Denali Therapeutics Inc. DNLI Income Statement

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17
Collaboration revenue:
Collaboration revenue from customers
3,604	4,766	13,604	4,197	4,205	125,676	1,195	1,648	641	-	0	0	-
Other collaboration revenue
52	-	-	-	94	-	-	-	-	-	-	-	-
Operating expenses:
Research and development
51,016	51,551	52,544	51,884	37,403	39,909	30,321	52,134	20,819	18,471	18,515	19,004	18,470
General and administrative
12,555	10,879	11,215	15,076	9,310	11,045	8,838	6,896	5,570	5,069	3,773	3,564	3,274
Total operating expenses
63,571	62,430	63,759	66,960	46,713	50,954	39,159	59,030	26,389	23,540	22,288	22,568	21,744
Loss from operations
-59,967	-57,758	-50,155	-62,763	-42,508	74,722	-37,964	-57,382	-25,748	-23,540	-22,288	-22,568	-21,744
Interest and other income, net
3,069	3,808	3,782	4,113	3,516	2,811	2,593	2,658	2,070	653	444	434	424
Loss before income taxes
-56,898	-53,950	-46,373	-58,650	-38,992	-	-35,371	-54,724	-	-	-	-	-
Income tax benefit
-100	0	-100	-300	0	-	0	0	-	-	-	-	-
Net loss
-56,763	-54,025	-46,260	-58,337	-38,992	77,533	-35,371	-54,724	-23,678	-22,887	-21,844	-22,134	-21,320
Other comprehensive income (loss):
Net unrealized gain on marketable securities, net of tax
485	-212	-317	547	981	767	77	-206	-919	-131	140	18	-22
Comprehensive loss
-56,278	-54,237	-46,577	-57,790	-38,011	78,300	-35,294	-54,930	-24,597	-23,018	-21,704	-22,116	-21,342
Net loss per share, basic and diluted (usd per share)
-0.55	-0.57	-0.48	-0.61	-0.41	0.84	-0.38	-0.59	-0.26	0.90	-2.14	-2.29	-2.36
Weighted average number of shares outstanding, basic and diluted (in shares)
102,419	96,093	95,859	95,495	94,984	94,362	93,665	92,899	89,560	30,937	10,231	9,670	9,017